<PAGE> 1
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. )
FILED BY THE REGISTRANT [X] FILED BY A PARTY OTHER THAN THE REGISTRANT [ ]
- --------------------------------------------------------------------------------
Check the appropriate box:
[ ] Preliminary Proxy Statement
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to [Section].240.14a-11(c) or
[Section].240.14a-12
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
SERAGEN INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement)
PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):
[ ] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee
is calculated and state how it was determined):
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
2) Form, Schedule or Registration Statement No.:
3) Filing Party:
4) Date Filed:
- --------------------------------------------------------------------------------
<PAGE> 2
[SERAGEN LOGO]
November 20, 1996
Dear Seragen Shareholder:
You are cordially invited to attend a Special Meeting of Shareholders of
Seragen, Inc. to be held at the offices of the Company, 97 South Street,
Hopkinton, Massachusetts, on December 18, 1996 at 11:00 a.m., local time.
At the Special Meeting, the Company will seek shareholder approval of a
proposal to amend the Company's Restated Certificate of Incorporation to
increase the number of authorized shares of the Company's common stock. The
Board of Directors recommends approval of this proposal. Such other business
will be transacted as may properly come before the Special Meeting.
Whether you plan to attend the Special Meeting or not, it is important that
you please sign, date and return the enclosed proxy card promptly. This will
ensure your proper representation at the Special Meeting.
We look forward to seeing you on December 18th.
Sincerely,
/s/ Reed R. Prior
Reed R. Prior
Chairman, Chief Executive
Officer and Treasurer
[SERAGEN TELEPHONE NUMBER LOGO]
<PAGE> 3
SERAGEN, INC.
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS
DECEMBER 18, 1996
Notice is hereby given that a Special Meeting of Shareholders of Seragen,
Inc. (the "Company") will be held at the offices of the Company, 97 South
Street, Hopkinton, Massachusetts, on December 18, 1996 at 11:00 a.m. for the
following purposes:
1. To consider and act upon a proposal to amend and restate the
Company's Restated Certificate of Incorporation to increase the number of
authorized shares of the Company's common stock from 30 million shares to
70 million shares.
2. To transact such other business as properly may come before the
Special Meeting or any adjournments thereof.
The Board of Directors has fixed the close of business on October 31, 1996
as the record date for the determination of shareholders entitled to notice of
and to vote at the Special Meeting and at any adjournments thereof. All
shareholders are cordially invited to attend the Special Meeting. However, to
ensure your representation you are requested to complete, sign, date and return
the enclosed proxy as soon as possible in accordance with the instructions on
the proxy card. A return addressed envelope is enclosed for your convenience.
By Order of the Board of Directors,
/s/ Jeffrey M. Wiesen
Jeffrey M. Wiesen, Esq.
Secretary
SERAGEN, INC.
97 South Street
Hopkinton, Massachusetts 01748
November 20, 1996
<PAGE> 4
SERAGEN, INC.
97 SOUTH STREET
HOPKINTON, MASSACHUSETTS 01748
PROXY STATEMENT
SPECIAL MEETING OF SHAREHOLDERS
TO BE HELD ON DECEMBER 18, 1996
GENERAL INFORMATION
This Proxy Statement is furnished in connection with the solicitation by
the Board of Directors of Seragen, Inc. (the "Company") of proxies to be voted
at a Special Meeting of Shareholders of the Company ("Special Meeting") on
December 18, 1996, and at any and all adjournments thereof. This Proxy Statement
and the accompanying proxy card are being mailed to Shareholders on or about
November 20, 1996.
Only Shareholders of record of the Company's 16,963,975 shares of Common
Stock, $0.01 par value per share (the "Common Stock") outstanding as of close of
business on October 31, 1996 will be entitled to vote. Each share of Common
Stock is entitled to one vote at the meeting.
VOTING AND QUORUM
Shareholders are urged to read carefully the material in this Proxy
Statement; specify their choice on the matter by marking the appropriate box on
the enclosed proxy card; and sign, date and return the card in the enclosed
stamped envelope. Where a shareholder specifies a choice on the proxy as to how
his or her shares are to be voted on a particular matter, the shares will be
voted accordingly. If no choice is specified, the shares will be voted FOR the
proposal to amend and restate the Company's Restated Certificate of
Incorporation to increase the authorized Common Stock. A shareholder who signs a
proxy by written instrument to the Company may revoke or revise that proxy at
any time before the Special Meeting by delivering to the Company a written
notice of revocation or a duly executed Proxy bearing a later date, or by voting
by ballot at the Meeting.
The holders of a majority of the issued and outstanding shares of Common
Stock of the Company entitled to vote at the Special Meeting must be represented
in person or by proxy at the Special Meeting for the Special Meeting to be held.
The affirmative vote of a majority of the shares present or represented and
entitled to vote at the Special Meeting is required to approve the proposal.
With respect to the tabulation of votes on any matter, abstentions are treated
as votes against a proposal, while broker non-votes have no effect on the vote.
PROXY SOLICITATION
The cost of the solicitation of proxies will be borne by the Company. In
addition to solicitation by mail, directors and officers of the Company, without
receiving any additional compensation, may solicit proxies personally or by
telephone or facsimile. The Company will request brokerage houses, banks, and
other custodians or nominees holding stock in their names for others to forward
proxy materials to their customers or principals who are the beneficial owners
of shares and will reimburse them for their expenses in doing so.
<PAGE> 5
PROPOSAL 1: AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION
TO INCREASE AUTHORIZED COMMON STOCK
On November 6, 1996, the Board unanimously adopted a resolution proposing
that the Company amend and restate its Restated Certificate of Incorporation to
increase the number of authorized shares of Common Stock from 30 million to 70
million. That proposed amendment and restatement of the Company's Restated
Certificate of Incorporation is now being submitted for Shareholder approval.
As of November 6, 1996, the Company had 16,963,975 shares of Common Stock
outstanding. In addition, as of that date, there were 191,155 shares of Common
Stock issuable upon the exercise of outstanding options under the Company's 1981
Stock Option Plan, 1,398,162 shares of Common Stock issuable upon the exercise
of outstanding options under the Company's 1992 Long Term Incentive Plan and
36,000 shares of Common Stock issuable upon the exercise of outstanding options
under the Company's 1992 Non-Employee Director Non-Qualified Stock Option Plan.
All of the remaining 11,410,708 shares of authorized and unissued shares of
Common Stock have been reserved for issuance upon exercise of warrants and
conversion of preferred stock issued in connection with the Company's previous
financings leaving no unreserved and unissued shares of Common Stock available
for future issuance.
A portion of the shares of Common Stock for which authorization is sought
in this proposal may be issued upon exercise of outstanding warrants and
conversion of outstanding preferred stock. A portion of the shares of Common
Stock will also be reserved for issuance under the Company's 1992 Long Term
Incentive Plan. On November 6, 1996, the Board adopted a resolution increasing
the number of shares available under the Plan from 2,300,000 to 8,000,000. The
Company has agreed to issue stock options to purchase a substantial number of
shares of Common Stock in connection with its recent restructuring of senior
management. The Company has no other plans or proposals at this time for the use
of the remaining shares of Common Stock for which authorization is sought.
The Company expects to incur substantial research and development expenses
as it continues the development of its fusion proteins. The Company also expects
to incur substantial administrative and commercialization expenses in the
future. The Company plans to finance its substantial cash need with potential
future debt or equity financings. The Company does not presently have unissued
and unreserved shares of Common Stock available to pursue equity financings and
achieve other goals which entail the issuance of Common Stock.
In addition to allowing the Company to raise capital, management believes
that the proposed amendment to Article Fourth of the Company's Restated
Certificate of Incorporation will provide several long-term advantages to the
Company and its shareholders. The passage of the proposal would enable the
Company to pursue acquisitions or enter into collaborative partnerships or other
transactions which management believes will enhance its development efforts and
to consummate transactions which, if they could be accomplished, might enhance
shareholder value. In addition, the Company has an obligation to repurchase
stock issued to investors in connection with the formation of Seragen
Biopharmaceuticals, Ltd., ("SBL") if certain conditions are met and the
investors elect to put their SBL shares to the Company. The Company has the
option to purchase such securities with up to 1,500,000 shares (subject to
adjustment) of the Company's Common Stock, or a combination of cash and Common
Stock, in lieu of cash. This option gives the Company flexibility and would
allow the Company to conserve cash needed for other purposes when the put rights
are exercised. The Company will only be able to avail itself of this option,
however, if it has a sufficient number of shares of Common Stock available for
issuance at that time. The additional shares of Common Stock for which
authorization is sought may also be used to purchase assets or services, to
retain consultants or to compensate employees.
2
<PAGE> 6
If additional shares are available, transactions dependent upon the
issuance of additional shares would be less likely to be undermined by delays
and uncertainties occasioned by the need to obtain shareholder authorization
prior to the consummation of such transactions. The ability to issue shares, as
deemed in the Company's best interests by the Board, will also permit the
Company to avoid the expenses which would be incurred in holding special
shareholders' meetings at a later date.
The Board has proposed a substantial increase in authorized Common Stock.
Such an increase is designed to provide flexibility to the Company's management.
However, these additional shares, if issued, will have a substantial dilutive
effect on present shareholders. In addition, the authorization of such a
substantial increase in the authorized Common Stock, while providing desirable
flexibility in connection with possible equity financings and other corporate
purposes, could have the effect of making it more difficult for a third party to
acquire, or of discouraging a third party from acquiring, a majority of the
outstanding voting stock of the Company. Even if the amendment to the Company's
Restated Certificate of Incorporation is approved, there can be no assurance
that additional equity financings will be available on acceptable terms, if at
all, to fund the Company's future working capital requirements, or that other
sources of financing, including partnerships, will be available.
In the event the proposal is passed, shareholder approval of the issuance
of the 40 million additional shares of Common Stock will not be sought prior to
the issuance of additional securities unless such issuances relate to a merger,
consolidation or other transaction which requires Shareholder approval.
Accordingly, the following resolution will be offered at the meeting.
RESOLVED, that Paragraph A of Article FOURTH of the Restated Certificate of
Incorporation of the Company be amended to read as follows:
FOURTH: A. The total number of shares of all classes of stock which
the Corporation shall have authority to issue is 75,000,000, consisting of
seventy million (70,000,000) shares of common stock, par value one cent
($0.01) per share (the "Common Stock") and five million (5,000,000) shares
of preferred stock, par value one cent ($0.01) per share (the "Preferred
Stock").
THE BOARD OF DIRECTORS RECOMMENDS APPROVAL OF THE ADOPTION OF AN AMENDMENT
AND RESTATEMENT OF THE FOURTH ARTICLE OF THE COMPANY'S RESTATED CERTIFICATE OF
INCORPORATION TO INCREASE THE AUTHORIZED SHARES OF COMMON STOCK OF THE COMPANY
FROM 30 MILLION SHARES TO 70 MILLION SHARES.
SHARE OWNERSHIP
The following table sets forth certain information regarding the beneficial
ownership of the Company's Common Stock as of November 6, 1996 by (i) each
person known by the Company to own beneficially 5% or more of its outstanding
Common Stock, (ii) each Director of the Company, (iii) the chief executive
officer and each of the four most highly compensated executive officers of the
Company whose total annual salary and bonus exceeded $100,000 for the fiscal
year ended December 31, 1995, and (iv) all Directors and executive officers as a
group. Except as otherwise indicated, the named beneficial owner has sole voting
and investment power with respect to the shares beneficially owned.
<TABLE>
<CAPTION>
NUMBER OF PERCENTAGE OF
SHARES SHARES BENEFICIALLY
NAME AND ADDRESS(**) BENEFICIALLY OWNED(1) OWNED(2)
- --------------------------------------------------------- --------------------- -------------------
<S> <C> <C>
Boston University(3)(4)(5)............................... 22,613,123 72.3%
881 Commonwealth Avenue
Boston, MA 02215
</TABLE>
3
<PAGE> 7
<TABLE>
<CAPTION>
NUMBER OF PERCENTAGE OF
SHARES SHARES BENEFICIALLY
NAME AND ADDRESS(**) BENEFICIALLY OWNED(1) OWNED(2)
- --------------------------------------------------------- --------------------- -------------------
<S> <C> <C>
Leon C. Hirsch(3)(6)..................................... 6,255,681 26.9%
150 Glover Avenue
Norwalk, CT 06856
Turi Josefsen(3)(7)...................................... 2,681,005 13.6%
150 Glover Avenue
Norwalk, CT 06856
P.R.I.F., L.P.(8)........................................ 2,830,960 14.5%
John Bagalay, Jr., Ph.D., Esq.(5)(9)..................... 8,000 *
Gerald S. J. Cassidy(3)(10).............................. 1,816,509 9.7%
700 13th Street, N.W., Suite 400
Washington, DC 20005
Anthony J. Clemento(11).................................. 50,459 *
Kenneth G. Condon, C.P.A.(5)(12)......................... 9,200 *
Leonard F. Estis, Ph.D.(13).............................. 117,039 *
Norman A. Jacobs(14)..................................... 18,000 *
Thomas N. Konatich(15)................................... 49,103 *
George W. Masters(16).................................... 238,313 1.4%
John R. Murphy, Ph.D.(17)................................ 171,216 1.0%
Jean C. Nichols, Ph.D.(18)............................... 202,415 1.2%
Reed R. Prior(19)........................................ -- *
John R. Silber, Ph.D.(20)................................ 178,500 1.1%
All officers and directors as a group.................... 2,858,754 14.6%
</TABLE>
- ---------------
* Represents beneficial ownership of less than 1% of the Common Stock.
** Addresses are given for persons who beneficially own 5% or more the
Company's outstanding Common Stock only.
(1) For purposes of this table, a person or group of persons is deemed to have
"beneficial ownership" of any shares as of November 6, 1996 that such
person or persons has the right to acquire within 60 days after such date.
(2) Percentage of ownership is based on 16,963,975 shares of Common Stock
outstanding as of November 6, 1996.
(3) Total number outstanding includes 12,421,712 shares of Common Stock
issuable upon conversion of 23,800 shares of Series B Preferred Stock and
assumes that shares of Series B Preferred Stock are convertible at a
conversion price of $1.916, the conversion price in effect on November 6,
1996, based on the average of the closing sale prices of the Common Stock
for the ten consecutive trading days preceding that date.
(4) Includes 3,753,754 shares of Common Stock issuable upon conversion of 5,000
shares of Series C Preferred Stock and accrued dividends thereon and
assumes that shares of Series C Preferred Stock are convertible at a
conversion price of $1.332, the conversion price in effect on November 6,
1996, based on seventy-three percent (73%) of the average of the closing
bid prices of the Common Stock for the five consecutive trading days
preceding that date.
4
<PAGE> 8
(5) The Boston University Nominee Partnership is a partnership that was created
to act as the record holder of certain securities owned by Boston
University. Dr. Bagalay and Mr. Condon are general partners of such
partnership and are required to vote and take other actions with respect to
such shares of Common Stock as instructed by duly authorized officers of
Boston University. Officers of Boston University are duly authorized by the
actions of the Trustees of Boston University. General partners of the
Boston University Nominee Partnership (Dr. Bagalay and Mr. Condon) and the
Trustees of Boston University (Dr. Howell and Dr. Silber) disclaim
beneficial ownership of such shares. Includes 15,000 shares issuable upon
exercise of stock options exercisable within 60 days, a warrant to purchase
1,376,666 shares exercisable at $4.75 per share, a warrant to purchase
3,009,962 shares exercisable at $4.00 per share, 6,158,664 shares of Common
Stock issuable upon conversion of 11,800 shares of Series B Preferred Stock
and 3,753,754 shares of Common Stock issuable upon conversion of 5,000
shares of Series C Preferred Stock. Boston University has entered into a
Stockholders Agreement dated as of November 6, 1996 (the "Stockholders
Agreement") with Leon C. Hirsch, Turi Josefsen, Gerald S.J. Cassidy and
Loretta P. Cassidy (collectively, together with Boston University, the
"Stockholders"), and Reed R. Prior and the Company with respect to the
election of directors and other matters. Pursuant to this agreement, the
Stockholders have agreed to maintain the number of persons comprising the
Board of Directors at nine, not to elect more than two persons designated
by or affiliated with Boston University to the Board of Directors, and to
elect three outside directors with experience in the pharmaceutical
industry reasonably acceptable to Mr. Prior.
(6) Represents a warrant to purchase 816,666 shares exercisable at $4.75 per
share, a warrant to purchase 1,785,570 shares exercisable at $4.00 per
share and Series B Preferred Stock convertible into 3,653,445 shares of
Common Stock. Does not include 1,115,243 shares issuable upon exercise of
warrants and does not include, 1,565,762 shares of Common Stock issuable
upon conversion of 3,000 shares of Series B Preferred Stock held by Turi
Josefsen, Mr. Hirsch's wife, as to which Mr. Hirsch disclaims beneficial
ownership. Mr. Hirsch has entered a Stockholders Agreement with respect to
the election of directors. (See Footnote 5)
(7) Represents a warrant to purchase 350,000 shares exercisable at $4.75 per
share, a warrant to purchase 765,243 shares exercisable at $4.00 per share
and Series B Preferred Stock convertible into 1,565,762 shares of Common
Stock. Does not include 2,602,236 shares issuable upon exercise of warrants
and does not include, 3,653,445 shares of Common Stock issuable upon
conversion of 7,000 shares of Series B Preferred Stock held by Leon C.
Hirsch, Ms. Josefsen's husband, as to which Ms. Josefsen disclaims
beneficial ownership. Mr. Josefsen has entered a Stockholders Agreement
with respect to the election of directors. (See Footnote 5)
(8) Includes 2,584,638 shares of Common Stock issuable upon conversion of 3,325
shares of Series A Preferred Stock and accrued dividends thereon and
assumes that the shares of Series A Preferred Stock are convertible at a
conversion price of $1.332, the conversion price in effect on November 6,
1996, based on seventy-three percent (73%) of the average closing bid
prices of the Common Stock for the five consecutive trading days preceding
that date. P.R.I.F., L.P. ("PRIF") is a limited partnership, the sole
general partner of which is HB and Co., Inc. ("HB"). HB has the exclusive
authority to manage, control and administer investments and affairs of
PRIF. The holder of all the issued and outstanding shares of HB is Lillian
Brachfeld. Henry Brachfeld is the sole director of HB and, as the sole
executive officer of HB, is its President and Secretary. This information
is based solely on a Schedule 13D filed with the Securities and Exchange
Commission and dated June 21, 1996.
(9) Represents 8,000 shares issuable upon exercise of options held by Dr.
Bagalay that are exercisable within 60 days.
5
<PAGE> 9
(10) Includes 8,000 shares issuable upon exercise of options held by Mr. Cassidy
that are exercisable with 60 days, a warrant to purchase 233,332 shares
exercisable at $4.75 per share, a warrant to purchase 500,000 shares
exercisable at $4.00 per share and 1,043,841 shares of Common Stock
issuable upon conversion of 2,000 shares of Series B Preferred Stock. Mr.
Cassidy's shares of Series B Preferred Stock and warrant are owned jointly
with his wife, Loretta P. Cassidy. Mr. and Mrs. Cassidy have entered a
Stockholders Agreement with respect to the election of directors. (See
Footnote 5).
(11) Represents 50,459 shares issuable upon exercise of options held by Mr.
Clemento that are exercisable within 60 days. Mr. Clemento resigned as Vice
President of Regulatory Affairs effective November 1, 1996.
(12) Includes 8,000 shares issuable upon exercise of options held by Mr. Condon
that are exercisable within 60 days.
(13) Includes 115,903 shares issuable upon exercise of options held by Dr. Estis
that are exercisable within 60 days.
(14) Represents 18,000 shares issuable upon exercise of options held by Mr.
Jacobs that are exercisable within 60 days.
(15) Includes 48,198 shares issuable upon exercise of options held by Mr.
Konatich that are exercisable within 60 days. Mr. Konatich resigned as
Chief Financial Officer effective November 12, 1996.
(16) Includes 221,000 shares issuable upon exercise of options exercisable by
Mr. Masters within 60 days and a warrant to purchase 1,250 shares
exercisable at $10.00 per share. As part of the recent management
restructuring, Mr. Masters retired from his positions as Vice Chairman,
Chief Executive Officer, President and a member of the Board of Directors
effective November 6, 1996.
(17) Includes 120,166 shares issuable upon exercise of options held by Dr.
Murphy that are exercisable within 60 days.
(18) Includes 193,909 shares issuable upon exercise of options held by Dr.
Nichols that are exercisable within 60 days. As part of the recent
management restructuring, Dr. Nichols was elected President, Chief
Technology Officer and a member of the Company's Board of Directors
effective November 6, 1996. Pursuant to her employment agreement, the
Company has agreed to grant Dr. Nichols stock options exercisable for
1.275% of the Company's Common Stock on a fully diluted basis on or before
December 6, 1996. Certain stock options currently held by Dr. Nichols will
be cancelled at that time.
(19) Mr. Prior joined the Company as Chairman, Chief Executive Officer and
Treasurer on November 6, 1996. Pursuant to his employment agreement, the
Company has agreed to grant Mr. Prior stock options exercisable for 8.5% of
the Company's Common Stock on a fully diluted basis within thirty days
after his joining the Company. Certain stockholders of the Company and Mr.
Prior have entered an agreement with respect to the election of directors.
(See Footnote 5)
(20) Includes a warrant to purchase 7,500 shares exercisable at $10.00 per
share. Dr. Silber's shares and warrant are owned jointly with his wife,
Kathryn U. Silber.
DEADLINE FOR SUBMISSION OF SHAREHOLDER PROPOSALS FOR NEXT YEAR'S ANNUAL MEETING
The proxy rules adopted by the Securities and Exchange Commission provide
that certain shareholder proposals must be included in the Proxy Statement for
the Company's Annual Meeting. For a proposal to be considered for inclusion in
next year's proxy statement, it must be received by the Company no later than
December 20, 1996.
6
<PAGE> 10
ALL SHAREHOLDERS ARE URGED TO COMPLETE, SIGN, DATE AND RETURN THE
ACCOMPANYING PROXY CARD IN THE ENCLOSED ENVELOPE.
By Order of the Board of Directors
/s/ Jeffrey M. Wiesen, Esq.
Jeffrey M. Wiesen, Esq.
Secretary
Hopkinton, Massachusetts
November 20, 1996
7
<PAGE> 11
DETACH HERE SRQ 1
SERAGEN, INC.
97 SOUTH STREET, HOPKINTON, MA 01748
P PROXY FOR 1996 SPECIAL MEETING OF SHAREHOLDERS
R THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
O
X The undersigned hereby acknowledges receipt of the Seragen, Inc. Notice
Y of Special Meeting of Shareholders and Proxy Statement dated November 20,
1996 and revoking all previous proxies, hereby appoints Reed R. Prior and
Susan M. Letterie, or either of them, as the undersigned's attorneys-in-fact
and proxies, each with power of substitution and with all the powers the
undersigned would possess if present, to vote all shares of the common stock
of SERAGEN, INC. (the "Company") which the undersigned would be entitled to
vote if personally present at the Special Meeting of Shareholders to be held
on December 18, 1996 at 11:00 a.m. at the offices of the Company, 97 South
Street, Hopkinton, Massachusetts, and any adjournments thereof.
-----------
SEE REVERSE
CONTINUED AND TO BE SIGNED ON REVERSE SIDE SIDE
-----------
<PAGE> 12
DETACH HERE SRQ 1
[X] PLEASE MARK
VOTES AS IN
THIS EXAMPLE.
THE SHARES REPRESENTED HEREBY WILL BE VOTED AS DIRECTED BY THIS PROXY, BUT
IF NO DETERMINATION IS MADE THEY WILL BE VOTED FOR PROPOSAL 1. THE BOARD OF
DIRECTORS RECOMMENDS A VOTE FOR PROPOSAL 1.
FOR AGAINST ABSTAIN
1. TO APPROVE THE PROPOSAL TO AMEND AND RESTATE THE
CERTIFICATE OF INCORPORATION TO INCREASE THE [ ] [ ] [ ]
AUTHORIZED COMMON STOCK FROM 30 MILLION SHARES TO
70 MILLION SHARES.
In their discretion, the proxies are authorized to vote upon such other
matters as may lawfully come before the meeting and all adjournments
thereof.
MARK HERE
FOR ADDRESS [ ]
CHANGE AND
NOTE AT LEFT
NOTE: PLEASE DATE AND SIGN EXACTLY AS
YOUR NAME(S) APPEAR(S) HEREON. IF ACTING
AS ATTORNEY, EXECUTOR, TRUSTEE, OR IN
ANY OTHER REPRESENTATIVE CAPACITY, SIGN
NAME AND TITLE.
Signature Date Signature Date
---------------- ------- ---------------- -------
